- 公司资讯
- finviz | 2022年09月20日 04:30Celsion Corporation Announces Company Name Change to Imunon, Inc.
- finviz | 2022年09月15日 20:30Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
- finviz | 2022年09月13日 06:30Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
- finviz | 2022年09月07日 21:15Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- finviz | 2022年09月01日 20:30Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
- finviz | 2022年08月30日 18:42CLSN: Complete Enrollment of OVATION 2 Study Expected in 3Q22
- finviz | 2022年08月15日 20:00Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
- finviz | 2022年08月08日 20:30Celsion Corporation to Hold Second Quarter 2022 Financial Results and
- finviz | 2022年07月19日 20:35Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
- finviz | 2022年07月19日 20:30Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
- finviz | 2022年06月24日 20:35Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
- finviz | 2022年06月22日 04:21UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd
- finviz | 2022年06月21日 20:35Life Sciences Investor Forum: Company Executives Present Live June 23rd
- finviz | 2022年06月21日 20:30Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
- finviz | 2022年06月13日 19:00CLSN: OVATION 2 Study 85% Enrolled
- finviz | 2022年05月16日 20:00Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
首页
上页
下页